ConductScience.org, home

Paper19251630

Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.

Hugonnet JE and 4 others. Science, 2009. Cited by 391 papers, by iCite.

Cite this record

ConductScience Library. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Papers, record 19251630. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19251630

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
PubMed
Journal
Science
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
391
iCite
Relative citation ratio, by iCite
11.5
iCite
Revised in PubMed
2025-05-29
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hugonnet JEJean-Emmanuel
2Tremblay LWLee W
3Boshoff HIHelena I
4Barry CE 3rdClifton E
5Blanchard JSJohn S

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntitubercularMajor topic
Clavulanic AcidMajor topic
Drug Resistance, Multiple, BacterialMajor topic
Extensively Drug-Resistant TuberculosisMajor topic
Mycobacterium tuberculosisMajor topic
ThienamycinsMajor topic
beta-LactamasesMajor topic
Acylation
Catalytic Domain
Crystallography, X-Ray
Drug Combinations
Enzyme Inhibitors
Humans
Kinetics
Mass Spectrometry
Meropenem
Microbial Sensitivity Tests
beta-Lactamase Inhibitors

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z01 AI000693Intramural NIH HHSUnited StatesZIAAI000693PubMed and NIHNIH RePORTER
Wellcome TrustUnited KingdomPubMedPubMed
AI33696NIAID NIH HHSUnited StatesR01AI033696PubMed and NIHNIH RePORTER
ZIAAI000783NIHNIH RePORTER

Download CSV of grants

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118408028The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation.J Bacteriol2008https://conductscience.org/library/papers/18408028PubMed
214977534Persistent and dormant tubercle bacilli and latent tuberculosis.Front Biosci2004https://conductscience.org/library/papers/14977534PubMed
37049231Inhibition of the RTEM beta-lactamase from Escherichia coli. Interaction of the enzyme with derivatives of olivanic acid.Biochemistry1982https://conductscience.org/library/papers/7049231PubMed
49624510Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.Antimicrob Agents Chemother1998https://conductscience.org/library/papers/9624510PubMed
58675308An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.Infect Immun1996https://conductscience.org/library/papers/8675308PubMed
69634230Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.Nature1998https://conductscience.org/library/papers/9634230PubMed
76416162In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.Antimicrob Agents Chemother1983https://conductscience.org/library/papers/6416162PubMed
815081094The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.Int J Antimicrob Agents2004https://conductscience.org/library/papers/15081094PubMed
915608701Tuberculosis - metabolism and respiration in the absence of growth.Nat Rev Microbiol2005https://conductscience.org/library/papers/15608701PubMed
1017084757Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.Lancet2006https://conductscience.org/library/papers/17084757PubMed
1116870770Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.Antimicrob Agents Chemother2006https://conductscience.org/library/papers/16870770PubMed
1215699201Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics.Microbiology (Reading)2005https://conductscience.org/library/papers/15699201PubMed
1318422342Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.Biochemistry2008https://conductscience.org/library/papers/18422342PubMed
1410549364How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention.Adv Exp Med Biol1998https://conductscience.org/library/papers/10549364PubMed
159564467Activity of amoxicillin/clavulanate in patients with tuberculosis.Clin Infect Dis1998https://conductscience.org/library/papers/9564467PubMed
1617915954Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate.Biochemistry2007https://conductscience.org/library/papers/17915954PubMed
1714670344M. tuberculosis persistence, latency, and drug tolerance.Tuberculosis (Edinb)2004https://conductscience.org/library/papers/14670344PubMed

Download CSV of references

Cited by254

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 391 citations.

PMIDTitleJournalYearIn PapersSource
42337014Genetic interference of distinctive Mycobacterium tuberculosis peptidoglycan modifications enhances β-lactam susceptibility and reveals expression-sensitive host immune dynamics.Sci Rep2026https://conductscience.org/library/papers/42337014PubMed
42170912Peptide Mimetic Platform for Activity Profiling of Mycobacterial l,d-Transpeptidases.Biochemistry2026https://conductscience.org/library/papers/42170912PubMed
42030160The mycobacterial ATP burst is a lysis artifact and serves as an assay for drug-induced cell wall damage.Cell Rep2026https://conductscience.org/library/papers/42030160PubMed
41925602A historical budget impact and expenditure analysis of meropenem and clavulanate-based treatment for adults with XDR-TB at a specialised TB hospital in South Africa.S Afr Fam Pract (2004)2026https://conductscience.org/library/papers/41925602PubMed
41676486Activity Profiling of Mycobacterial L,D-Transpeptidases.bioRxiv2026https://conductscience.org/library/papers/41676486PubMed
41463713Peptidoglycan LD-Transpeptidases.Antibiotics (Basel)2025https://conductscience.org/library/papers/41463713PubMed
41354769Effects of CwlM, a peptidoglycan synthesis regulator, on beta-lactam tolerance and host-pathogen interactions.BMC Microbiol2025https://conductscience.org/library/papers/41354769PubMed
41279242The mycobacterial ATP burst is a lysis artifact and serves as an assay for drug-induced cell wall damage.bioRxiv2025https://conductscience.org/library/papers/41279242PubMed
41207943Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis.Adv Exp Med Biol2026https://conductscience.org/library/papers/41207943PubMed
41026774The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clin Infect Dis2026https://conductscience.org/library/papers/41026774PubMed
40990707New drugs for the management of tuberculosis.Curr Opin Infect Dis2025https://conductscience.org/library/papers/40990707PubMed
40980328Progress of anti-tuberculosis drug targets and novel therapeutic strategies.Front Microbiol2025https://conductscience.org/library/papers/40980328PubMed
40952390Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40952390PubMed
40854973Strategic design of a multi-tier database for class A β-lactamase BlaC variants of M. tuberculosis: advancing the fight against antibacterial resistance.J Antibiot (Tokyo)2025https://conductscience.org/library/papers/40854973PubMed
40657634Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review.GMS Hyg Infect Control2025https://conductscience.org/library/papers/40657634PubMed
40637416Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis.mBio2025https://conductscience.org/library/papers/40637416PubMed
40455216A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis.Clin Infect Dis2025https://conductscience.org/library/papers/40455216PubMed
40428869The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review.Medicina (Kaunas)2025https://conductscience.org/library/papers/40428869PubMed
40295972Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.BMC Infect Dis2025https://conductscience.org/library/papers/40295972PubMed
40020440Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.Drug Resist Updat2025https://conductscience.org/library/papers/40020440PubMed

See all 254 cited byDownload CSV of cited by

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
PDB3DWZ

Source PDB

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19251630

GET https://conductscience.org/api/papers/v1/19251630/cited_by?page=2